Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Blood Rev. 2019 Nov 2;40:100636. doi: 10.1016/j.blre.2019.100636

Table 3-.

The studies about the outcome of high dose melphalan followed by autologous stem cell transplantation.

The study Number of patients Cardiac involvement % Complete Hematological response % Organ response % Treatment related mortality % Median PFS/OS
Gertz 2010 434 Not rported 39 47 10 Complete response
>120 m
Partial response
107m
No response 32 m
Sanchorawala Blood 2011 421 45 34 53 11.4 Med OS 75m
Sanchorawala 2014 607 53 34 NR 9 Med OS 80m
Parmar 2014 80 23 19 39 12.5 5 years OS 72%
Jaccard 2007 100 - randomized to ASCT or MP 73 No significant difference between the two treatment groups (47% Vs 61%) No significant difference between the two treatment groups 24 Med OS was 56.9 months in the MP arm and 22.2 months in the ASCT arm (P=0.04)
Gertz 2016 89 – randomized to ASCT (55) or Mel dex (39) 41 in mel dex arm and 15 in ASCT arm 20, No significant difference between the two treatment groups 30 No significant difference between the two treatment groups 5.6 3-year PFS of 29.1% in mel dex arm and 51.7% in the ASCT arm. 3y OS was 58.8% in mel dex arm vs 83.6% in ASCT arm.